PT  - JOURNAL ARTICLE
AU  - Janice P Dutcher
TI  - Update on the biology and management of renal cell carcinoma
AID  - 10.1136/jim-2018-000918
DP  - 2018 Nov 19
TA  - Journal of Investigative Medicine
PG  - jim-2018-000918
4099  - http://hw-f5-jim.highwire.org/content/early/2018/11/19/jim-2018-000918.short
4100  - http://hw-f5-jim.highwire.org/content/early/2018/11/19/jim-2018-000918.full
AB  - Renal cell cancer (RCC) (epithelial carcinoma of the kidney) represents 2%–4% of newly diagnosed adult tumors. Over the past 2 decades, RCC has been better characterized clinically and molecularly. It is a heterogeneous disease, with multiple subtypes, each with characteristic histology, genetics, molecular profiles, and biologic behavior. Tremendous heterogeneity has been identified with many distinct subtypes characterized. There are clinical questions to be addressed at every stage of this disease, and new targets being identified for therapeutic development. The unique characteristics of the clinical presentations of RCC have led to both questions and opportunities for improvement in management. Advances in targeted drug development and understanding of immunologic control of RCC are leading to a number of new clinical trials and regimens for advanced disease, with the goal of achieving long-term disease-free survival, as has been achieved in a proportion of such patients historically. RCC management is a promising area of ongoing clinical investigation.